Clinical research

Three-year clinical outcome of percutaneous treatment of bifurcation lesions in multivessel coronary artery disease with the sirolimus-eluting stent: insights from the Arterial Revascularisation Therapies Study, part II (ARTS II)

EuroIntervention 2009;5:190:196.

H Routledge
Helen C. Routledge1, MD; Thierry Lefèvre1*, MD; Antonio Colombo2, MD; Keith G. Oldroyd3, MD; Christian W. Hamm4, MD; Giulio Guagliumi5, MD; Wolfgang von Scheidt6, MD; Victor Guetta7, MD; Witold Ruzyllo8, MD; Kristel Wittebols9, MSc; Dick M. Goedhart10, PhD; Patrick W. Serruys11, MD, PhD
1. Institut Cardiovasculaire Paris Sud, Massy, France; 2. EMO Centro Cuore Colombus and San Rafaele Hospital, Milan, Italy; 3. Lanarkshire Acute Hospitals, Glasgow, United Kingdom; 4. Kerckhoff Klinik, Kardiologie, Bad Nauheim, Germany; 5. Azienda Ospedal

Aims: The long-term impact of treating bifurcation lesions on the overall outcome of patients with multivessel coronary disease treated percutaneously with drug-eluting stents is unknown. This analysis determined the influence of bifurcation treatment using sirolimus-eluting stents on 3-year clinical outcomes.

Methods and results: Of the 607 patients (2,160 lesions) in the ARTS II study, 324 patients underwent revascularisation procedures involving treatment of at least one bifurcation (465 lesions). Three-year outcomes were compared to those without bifurcations. Despite more diffuse and complex disease in the bifurcation group, survival free of adverse events was equivalent in the two groups. At 3-years, there was ...

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

angioplastysirolimus-eluting stentstent thrombosis
Read next article
Long-term outcome after the V stenting technique in de novo bifurcation lesions using drug-eluting stents

Latest news